Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA ®) platform to develop a new class of genetic medicines for rare ...
ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results